20:34 , Jul 14, 2017 |  BioCentury  |  Strategy

Back to Ipsen’s roots

After spending the last six years plugging revenue holes via licensing and M&A, Ipsen Group is once again on track to meet the 2020 financial targets it set at the beginning of the decade. But...
19:43 , Apr 7, 2017 |  BC Week In Review  |  Company News

Emergent BioSolutions, HHS infectious news

Emergent signed a modification to its contract with HHS’s Biomedical Advanced Research and Development Authority (BARDA) to manufacture and deliver botulism antitoxin heptavalent (BAT) to the U.S. Strategic National Stockpile. The modification is valued at...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

Anthrasil anthrax immune globulin IV regulatory update

FDA approved a BLA from Emergent for Anthrasil anthrax immune globulin IV (AIGIV) to treat inhalational anthrax in combination with antibacterial drugs. The approval triggered a $7 million payment to Emergent from HHS’s Biomedical Advanced...
02:02 , Mar 26, 2015 |  BC Extra  |  Company News

Emergent's anthrax treatment gets FDA nod

FDA approved a BLA for Anthrasil anthrax immune globulin IV (AIGIV) from Emergent BioSolutions Inc. (NYSE:EBS) to treat inhaled anthrax. The drug, developed using plasma collected from healthy donors vaccinated with the company's BioThrax ,...
08:00 , Jan 15, 2015 |  BC Innovations  |  Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

Emergent BioSolutions, U.S. Centers for Disease Control and Prevention infectious news

Emergent said the CDC exercised options under a 2012 award valued at $18.9 million over three years for Emergent to supply Vaccinia Immune Globulin Intravenous (VIGIV) for the U.S. strategic national stockpile. The purified antibody...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Clinical News

Anthrax immune globulin IV regulatory update

Emergent submitted a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. Emergent gained rights to the product - a solution of human polyclonal antibodies that target anthrax toxins - through...
02:14 , Aug 8, 2014 |  BC Extra  |  Company News

Emergent submits BLA for anthrax treatment

Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) submitted a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. Emergent gained rights to the product -- a solution of human polyclonal antibodies that...
07:00 , Mar 31, 2014 |  BC Week In Review  |  Company News

Emergent BioSolutions, Mapp Biopharmaceutical, Zalgen Labs, Ben-Gurion University of the Negev, NIH, Public Health Agency of Canada, Scripps Research Institute,

NIH's National Institute of Allergy and Infectious Disease (NIAID) awarded a consortium led by Scripps a five-year grant worth up to $28 million to develop immunotherapies for filoviruses and arenaviruses that cause severe hemorrhagic fever,...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Company News

Cangene, Emergent BioSolutions deal

Biodefense company Emergent completed the acquisition of Cangene for $3.24 per share in cash or $222 million in cash (see BioCentury, Dec. 16, 2013). Cangene Corp. , Winnipeg, Manitoba   Emergent BioSolutions Inc. (NYSE:EBS), Rockville,...